Tesamorelin is gaining increasing popularity in biohacking and body composition optimisation circles due to its ability to stimulate natural growth hormone (GH) production, reduce visceral fat, support lean muscle mass, and improve metabolic function without the need for direct exogenous GH administration. Although tesamorelin has been FDA-approved solely for the treatment of HIV-related lipodystrophy and not for bodybuilding or performance enhancement, clinical studies show it can significantly improve body composition by reducing deep abdominal fat while supporting muscle quality and metabolic health [1–6]. For this reason, the topic of „Tesamorelin in Biohacking” is becoming increasingly popular among individuals interested in longevity, regeneration, and metabolic optimisation.
Tesamorelin functions as a stabilised analogue of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to increase the secretion of endogenous GH, which subsequently elevates insulin-like growth factor-1 (IGF-1) levels [1,2]. Unlike direct recombinant growth hormone injections, tesamorelin acts via the body's intrinsic hormonal signalling system and supports a more physiological, pulsatile release of GH. Increased GH and IGF-1 activity contributes to enhanced lipolysis, improved protein synthesis, mitochondrial activity, tissue regeneration, and metabolic regulation, which explains why tesamorelin is often analysed in protocols related to body recomposition and recovery [1–4].
One of the main reasons for the interest in tesamorelin within biohacking and body composition improvement is the strong clinical evidence regarding the reduction of visceral adipose tissue (VAT). Visceral fat is deep abdominal fat associated with metabolic disorders, insulin resistance, inflammation and a deterioration in body composition. In a pooled phase III study involving HIV-positive individuals with excess abdominal fat, Falutz et al. (2010) demonstrated that tesamorelin reduced VAT by approximately 15.4% over 26 weeks, whilst improving triglyceride levels and cholesterol ratios [3]. Long-term studies have further shown that the reduction in abdominal fat could persist for up to 52 weeks with continued therapy [4]. Unlike many weight-loss methods, which reduce both visceral and subcutaneous fat in a non-selective manner, tesamorelin appears to preferentially target metabolically harmful visceral fat whilst preserving subcutaneous tissue and lean body mass.
Tesamorelin has also shown effects related to the improvement of muscle quality and regeneration. Adrian et al. (2019) analysed participants from clinical trials of tesamorelin and reported a significant increase in muscle density and muscle cross-sectional area in individuals who achieved a substantial reduction in visceral fat [5]. Improvement was observed in several trunk muscle groups, suggesting a beneficial effect on muscle quality and lean tissue preservation. Since GH and IGF-1 signalling affect collagen synthesis, protein turnover, tissue regeneration, and cellular repair, tesamorelin is often discussed in biohacking communities in the context of training recovery, body recomposition, and healthy physical ageing.
Another important area of body composition optimisation associated with tesamorelin is liver health and metabolic function. Stanley et al. (2014) demonstrated that tesamorelin significantly reduced both visceral fat and hepatic fat in HIV-positive individuals with abdominal fat accumulation [6]. In the case of HIV-associated non-alcoholic fatty liver disease (NAFLD), Stanley et al. (2019) subsequently reported a relative reduction in hepatic fat of approximately 37% after 12 months of therapy [7]. Fourman et al. (2020) further demonstrated that tesamorelin improved the expression of genes associated with mitochondrial function, oxidative phosphorylation and lipid metabolism, whilst reducing inflammatory pathways and liver fibrosis [8]. Improved liver function and mitochondrial energy production are often considered key components of metabolic optimisation and longevity strategies.
Tesamorelin also demonstrated a potential impact on energy metabolism and regenerative capacity. Makimura and colleagues (2014) showed that tesamorelin-induced IGF-1 increase was associated with improved phosphocreatine resynthesis and mitochondrial function in obese adults with diminished GH secretion [9]. Enhanced mitochondrial efficiency may contribute to improved post-exercise recovery, more effective energy utilisation, greater metabolic flexibility, and overall physical resilience.
Unlike anabolic steroids or direct GH therapy, tesamorelin typically leads to a more moderate and physiological increase in GH and IGF-1 levels. Clinical studies have repeatedly demonstrated increases in IGF-1 while maintaining relatively stable fasting glucose and HbA1c levels in most participants [3,6,7]. However, as tesamorelin activates the GH-IGF-1 axis, there can still be adverse effects related to increased GH activity. The most commonly reported include:
- Injection site reactions,
- water retention and mild swelling,
- joint pain or stiffness,
- Muscle discomfort,
- mild tingling,
- sporadic glucose intolerance or minor changes in blood sugar levels [1,3,4].
Due to these hormonal effects, monitoring IGF-1 levels and metabolic markers is usually recommended during therapy.
In discussions surrounding biohacking and bodybuilding, tesamorelin is often compared to other GH secretagogues such as CJC-1295, Ipamorelin, Sermorelin, or MK-677. However, tesamorelin stands out from these substances due to extensive clinical data in humans confirming reductions in visceral and hepatic fat, along with measurable improvements in metabolic parameters [3–8]. Many other peptides used for „GH optimization” rely more on anecdotal evidence, experimental applications, or small pharmacokinetic studies rather than large randomised controlled trials.
In summary, tesamorelin appears most useful for optimising body composition focused on visceral fat reduction, improving metabolic health, preserving lean tissue, and supporting regeneration, rather than extreme muscle hypertrophy or rapid weight gain. Current evidence suggests tesamorelin can improve abdominal fat distribution, reduce liver fat, enhance muscle quality, support mitochondrial function, and aid regenerative processes via physiological activation of endogenous GH and IGF-1 signalling. Despite growing interest in biohacking and physique enhancement circles, tesamorelin remains a prescription medication for specific medical indications and has not been officially approved for bodybuilding or performance enhancement purposes.
Disclaimer
The content is for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or endorsement of performance-enhancing drug use. Tesamorelin is an FDA-approved prescription medication for specific medical indications and has not been officially approved for bodybuilding, biohacking, or physique enhancement. Hormone therapies affecting the growth hormone and IGF-1 pathways can carry risks and should only be used under the supervision of a qualified healthcare professional with appropriate laboratory monitoring and individual medical assessment.
References
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548730/
- PubChem. (2025). Tesamorelin Compound Summary. National Centre for Biotechnology Information, National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
- Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicentre, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
- Falutz, J., Allas, S., Mamputu, J. C., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
- Adrian, S., Scherzinger, A., Sanyal, A., et al. (2019). Growth hormone-releasing hormone analogue tesamorelin reduces fat and increases muscle area in adults with HIV. The Journal of Frailty & Ageing, 8(3), 154–159. https://doi.org/10.14283/jfa.2018.45
- Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomised clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
- Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Agyapong, G., Torriani, M., Chung, R. T., & Grinspoon, S. K. (2019). Effect of tesamorelin on non-alcoholic fatty liver disease in HIV-positive individuals: A randomised, double-blind, multicentre study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
- Fourman, L. T., Billingsley, J. M., Agyapong, G., Ho Sui, S. J., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Corey, K. E., Torriani, M., Kleiner, D. E., Hadigan, C. M., Stanley, T. L., Chung, R. T., & Grinspoon, S. K. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5(16), e140134. https://doi.org/10.1172/jci.insight.140134
- Makimura, H., Murphy, C. A., Feldpausch, M. N., & Grinspoon, S. K. (2014). Effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. The Journal of Clinical Endocrinology & Metabolism, 99(1), 338–343. https://doi.org/10.1210/jc.2013-3436